AcelRx rally quickly fizzles after FDA offers a guarded warning about its latest pain drug pitch
A little less than a year after the FDA kicked back AcelRx’s sublingual jolt of the pain med sufentanil, Dsuvia (ARX-04), in search of more …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
